Comparative Pharmacology
Head-to-head clinical analysis: DURAGESIC 75 versus FENTORA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAGESIC 75 versus FENTORA.
DURAGESIC-75 vs FENTORA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent opioid agonist primarily at the mu-opioid receptor, exerting its analgesic effects by mimicking endogenous endorphins and enkephalins to activate G-protein-coupled inwardly rectifying potassium channels, leading to hyperpolarization and reduced neuronal excitability in pain pathways.
Fentanyl is a potent mu-opioid receptor agonist, binding to and activating opioid receptors in the brain and spinal cord, leading to analgesia and sedation.
Adults: Apply one 75 mcg/hr transdermal patch every 72 hours. Start with lower dose in opioid-naive patients.
For opioid-tolerant adults: 100 mcg (one tablet) placed in buccal cavity; titrate upward in increments of 100 mcg per breakthrough pain episode, with minimum 2-hour interval between doses; maximum 4 doses per day.
None Documented
None Documented
22-25 hours after removal of patch; increased in elderly, hepatic/renal impairment
Terminal elimination half-life is approximately 2–4 hours in adults, but can range from 2 to 6 hours depending on hepatic clearance. In elderly or hepatically impaired patients, half-life may be prolonged. The rapid initial decline is due to redistribution, and the terminal phase reflects slow elimination from deep compartments.
Renal (75% as metabolites, <10% unchanged), fecal (25%)
Primarily renal: Approximately 75% of the dose is excreted in urine as metabolites (mostly norfentanyl, despropionylfentanyl, and hydroxyfentanyl), with less than 7% as unchanged fentanyl. Fecal elimination accounts for about 9%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic